A multi-center, randomized, open label pivotal phase 3 study to compare the efficacy and safety of Carteyva to standard second-line therapy in adult subjects with relapse/refractory large B-cell lymphoma (r/r LBCL).

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 01 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Relmacabtagene-autoleucel (Primary)
Indications Diffuse large B cell lymphoma
Focus Registrational; Therapeutic Use
Sponsors JW Therapeutics

Most Recent Events

01 Apr 2022 New trial record
31 Mar 2022 According to a JW Therapeutics media release, the company has received the Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) of China for this pivotal clinical trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight